Although the prognosis for early breast cancer HR +, HER2- is good, 20-30% of patients may develop an incurable metastatic disease. A new treatment option is available for these patients.
The European Commission has approved the use of abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with early-stage breast cancer HR + and HER2-, node-positive and at high risk of relapse. The monarchE phase 3 randomized trial showed a statistically significant improvement in invasive disease-free survival in patients receiving abemaciclib plus hormone therapy compared with patients re...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
